fotolia_1202733_XS-1.jpg

Orthopaedic surgeons warn parents and young children about the dangers of trampolines

Posted On July 19, 2017 By OrthoSpineNews In Extremities /  

ROSEMONT, Ill., July 19, 2017 /PRNewswire-USNewswire/ — During the summer months, many children are drawn to indoor and outdoor trampolines for fun and physical activity. And yet, trampolines can be extremely dangerous, especially for children under age 6.

In 2015, there were more than 295,000 medically treated trampoline injuries in the U.S., according to the Consumer Product Safety Commission, including 102,943 emergency department visits.

“We want children to enjoy exercise and physical activity, especially during the summer months,” said AAOS spokesperson and Los Angeles pediatric orthopaedic surgeon Jennifer M. Weiss, MD, “but parents and caregivers should know about the dangers of trampolines and the risk for serious injury, especially in very young children. Children younger than age 6 are less likely to have the coordination, body awareness, and swift reaction time necessary to keep their bodies, bones and brains safe on trampolines.”

The dangers of trampoline use were recently highlighted when a 3-year-old Florida boy broke his femur (thigh bone) during routine jumping on a trampoline, requiring a full lower body cast, and causing him tremendous pain and discomfort.

The most common trampoline injuries are sprains and fractures resulting from falls on the trampoline mat, frame or springs; collisions with one or more jumpers; stunts gone wrong; and falls off the trampoline on the ground or other hard surface, according to CPSC.

As highlighted in the American Academy of Orthopaedic Surgeons’ position statement, “Trampolines and trampoline safety,” nearly one-third of trampoline injuries involved fractures; 60 percent of the fractures were located in the upper extremities and approximately 36 percent in the lower extremities. In addition:

Most trampoline injuries occur in the home environment, and more than 90 percent are sustained by children, usually those between the ages of 5 and 14 years. Although most injuries to children occur while they are unsupervised by parents or adults, many also occur when adults are present. More than half of injuries occur on the mat of the trampoline and three-fourths of injuries involve two or more children on the trampoline at the same time.

There is no data that shows a reduction in injury rates for trampolines outfitted with netting and/or other safety equipment.

The American Academy of Orthopaedic Surgeons recommends that parents and caregivers ensure the following to minimize and avoid trampoline injuries:

  • Do not allow children younger than 6 years of age to use trampolines.
  • Provide careful adult supervision, proper safety measures and instruction when trampolines are used for physical education, competitive gymnastics, diving training, and other similar activities.
  • Allow only one participant at a time to use a trampoline.
  • Ensure that spotters are present when participants are jumping. Somersaults or high-risk maneuvers should be avoided without proper supervision and instruction; these maneuvers should be attempted only with proper use of protective equipment, such as a harness.
  • Place the trampoline-jumping surface at ground level.
  • Ensure that supporting bars, strings, and surrounding landing surfaces have adequate protective padding that is in good condition and appropriately placed.
  • Regularly check equipment for safety conditions; discard worn or damaged equipment if replacement parts are unavailable
  • Do not rely on safety net enclosures for injury prevention; most injuries occur on the trampoline surface.
  • Remove trampoline ladders after use to prevent unsupervised access by young children.

More Information about the AAOS
With more than 39,000 members, the American Academy of Orthopaedic Surgeons is the world’s largest medical association of musculoskeletal specialists. The AAOS provides educational programs for orthopaedic surgeons and allied health professionals, champions and advances the highest quality musculoskeletal care for patients, and is the authoritative source of information on bone and joint conditions, treatments and related issues.

Visit AAOS, at:
Newsroom.aaos.org for bone and joint health news, stats, facts, images and interview requests.
ANationinMotion.org for inspirational patient stories, and orthopaedic surgeon tips on maintaining bone and joint health, avoiding injuries, treating musculoskeletal conditions and navigating recovery.
Orthoinfo.org for patient information on hundreds of orthopaedic diseases and conditions.
Facebook.org/AAOS1
Twitter.com/AAOS1

CONTACT: Kelly King Johnson, 847-384-4033, king@aaos.org; Sheryl Cash, 847-384-4032, scash@aaos.org

Read More
MSW-ortho-1-1.jpg

Mount Sinai Opens World-Class Orthopaedic Center on Manhattan’s West Side

Posted On July 14, 2017 By OrthoSpineNews In Extremities, Recon /  

(New York, NY – July 14, 2017) – Mount Sinai has announced the opening of the Orthopaedic Center at Mount Sinai West. The new facility, located at 425 West 59th Street, is the first of its kind on Manhattan’s West Side, with state-of-the-art equipment and exam rooms to enhance patient experience and care.

The Orthopaedic Center at Mount Sinai West will be the Health System’s location for all orthopedic patient appointments on the West Side. The new facility offers a larger space to accommodate more patients and physicians specializing in all areas of orthopedics. Four new surgeons have joined the center’s 12 existing physicians to expand care and services in the areas of total joint replacement, sports medicine, spine, foot and ankle, shoulder, elbow and hand injuries. This facility gives patients new and direct on-site access to radiologists, rheumatologists, and pain management physicians for  coordinated care.

Michael Bronson, MD, Chair, Department of Orthopaedics, Mount Sinai West; Chief, Joint Replacement Surgery, Mount Sinai West; and Associate Professor, Icahn School of Medicine at Mount Sinai, will direct the Orthopaedic Center at Mount Sinai West.

“We are extremely excited about the opening of our new facility, which will provide patients throughout the city and especially on the west side of Manhattan with state-of-the-art care, and give them access to orthopedic physicians in all sub-specialties,” said Dr. Bronson. “The Center will also provide immediate access to patients with acute orthopedic problems so these can be addressed in a timely manner. A larger facility means patients won’t have to wait weeks or months to see a world-renowned specialist.”

Additionally, the Orthopaedic Center at Mount Sinai West will serve as a major teaching site for medical students, residents, and fellows in all areas of orthopedics. This will add an extra level of expertise on the West Side, leading to increased medical research and breakthroughs in treatments to advance patient care.

“The Orthopaedic Center at Mount Sinai West represents Mount Sinai’s commitment to growth of the Department of Orthopaedics and signifies integration of care and dedication to patients on the West Side,” said Leesa Galatz, MD, System Chair, Orthopaedics, Mount Sinai Health System, and Mount Sinai Professor, Leni and Peter W. May Department of Orthopaedic Surgery, Icahn School of Medicine at Mount Sinai. “This is a center for excellence in orthopedics and patients will know that when they come here they will get exemplary care.”

About the Mount Sinai Health System
The Mount Sinai Health System is an integrated health system committed to providing distinguished care, conducting transformative research, and advancing biomedical education. Structured around seven hospital campuses and a single medical school, the Health System has an extensive ambulatory network and a range of inpatient and outpatient services—from community-based facilities to tertiary and quaternary care.

The System includes approximately 7,100 primary and specialty care physicians; 12 joint-venture ambulatory surgery centers; more than 140 ambulatory practices throughout the five boroughs of New York City, Westchester, Long Island, and Florida; and 31 affiliated community health centers. Physicians are affiliated with the renowned Icahn School of Medicine at Mount Sinai, which is ranked among the highest in the nation in National Institutes of Health funding per investigator. The Mount Sinai Hospital is in the “Honor Roll” of best hospitals in America, ranked No. 15 nationally in the 2016-2017 “Best Hospitals” issue of U.S. News & World Report.  The Mount Sinai Hospital is also ranked as one of the nation’s top 20 hospitals in Geriatrics, Gastroenterology/GI Surgery, Cardiology/Heart Surgery, Diabetes/Endocrinology, Nephrology, Neurology/Neurosurgery, and Ear, Nose & Throat, and is in the top 50 in four other specialties. New York Eye and Ear Infirmary of Mount Sinai is ranked No. 10 nationally for Ophthalmology, while Mount Sinai Beth Israel, Mount Sinai St. Luke’s, and Mount Sinai West are ranked regionally. Mount Sinai’s Kravis Children’s Hospital is ranked in seven out of ten pediatric specialties by U.S. News & World Report in “Best Children’s Hospitals.”

For more information, visit http://www.mountsinai.org/, or find Mount Sinai on Facebook, Twitter and YouTube.

Read More
PuraPly-Box-and-Product_update.png

PuraPly™ Antimicrobial Named One of Top 10 Innovations in Podiatry

Posted On July 13, 2017 By OrthoSpineNews In Biologics, Extremities /  

CANTON, Mass., July 13, 2017 /PRNewswire/ — PuraPlyTM Antimicrobial (PuraPlyTM AM), an FDA 510(k)-cleared wound management product from Organogenesis Inc., has been named one of the “Top 10 Innovations in Podiatry” by Podiatry Today, an award-winning publication that covers the latest developments in podiatric medicine.

PuraPly AM was selected as a top innovation for 2017 for its impact on reducing bioburden in wounds.

It is estimated that the majority of wounds possess biofilm, which can negatively impact tissue repair and delay healing if not addressed. With PuraPly AM, clinicians have a product solution to specifically address this challenge.

“A lot of times, debridement alone isn’t enough to prevent the reformation of biofilm,” said Ryan Fitzgerald, DPM, FACFAS, Associate Professor of Surgery at the University of South Carolina School of Medicine, in the article from Podiatry Today. “As part of a comprehensive biofilm-based wound management approach including sharp debridement, PuraPly AM provides a barrier that helps prevent biofilm re-formation and supports healing.”

PuraPly AM is an FDA 510(k)-cleared Class II medical device that is intended for management of a variety of acute and chronic wound types, including partial- and full-thickness wounds, pressure ulcers, surgical wounds, trauma wounds, venous and diabetic ulcers. PuraPly AM is unique in that it combines purified native collagen with PHMB, which provides broad antimicrobial coverage and protects against a wide range of bacteria that colonize wounds and can progress to biofilm formation and infection.

“Developing and manufacturing innovative products that serve our customers’ needs is at the heart of what we do, so it’s an honor for PuraPly AM to receive this distinction,” said Gary S. Gillheeney, Sr., President & CEO of Organogenesis Inc. “We’re pleased about the extremely positive reception this product has received since its 2015 launch and look forward to helping more wound care clinicians utilize PuraPly AM in the fight against bioburden and infection.”

For more information on PuraPly AM, click here.

About Organogenesis Inc.
Headquartered in Canton, Massachusetts, Organogenesis Inc. is a global leader in regenerative medicine, offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’ versatile portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.

Media Contact:
Angelyn Lowe
(781) 830-2353
alowe@organo.com

SOURCE Organogenesis Inc.

Related Links

http://organogenesis.com/

Read More
NASDAQ_WMGI-1.png

Wright Medical Group N.V. Highlights New Innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2017 Annual Meeting

Posted On July 12, 2017 By OrthoSpineNews In Extremities /  

AMSTERDAM, The Netherlands , July 12, 2017 (GLOBE NEWSWIRE) — Wright Medical Group N.V. (NASDAQ:WMGI) today announced that it will highlight new innovations at the American Orthopaedic Foot and Ankle Society (AOFAS) 2017 Annual Meeting taking place at the Washington State Convention Center in Seattle, Washington from July 12-15, 2017.

Wright will feature its full range of lower extremities and biologics products at exhibit booth #801 and will showcase, for the first time, three important additions to its foot and ankle portfolio:

INVISION™ Total Ankle Revision System – The first and only system developed specifically for total ankle revision arthroplasty, the INVISION Total Ankle Revision System provides a unique solution for even the most difficult revision procedures.  Whether leveraged as a standalone construct or in conjunction with INFINITY and INBONETM components, the INVISION Total Ankle Revision System is an important addition to the continuum of care from total ankle replacement through any necessary revisions.  The INVISION Total Ankle Revision System helps surgeons re-build bone lost through previous surgeries and provides modularity to help restore natural joint height.

ORTHOLOC™ 3Di Ankle Fracture Low Profile System – The ORTHOLOC 3Di Ankle Fracture Low Profile System features a complete range of ankle fracture plates designed specifically for the foot and ankle surgeon.  The system features low-profile, anatomic plate designs and ORTHOLOC 3Di polyaxial locking screw technology, providing an innovative fracture solution that addresses a primary need for one of the foot and ankle’s largest market segments.

MICA™ Minimally-Invasive Foot & Ankle System – As the first minimally invasive solution specifically designed for foot and ankle surgery, the MICA Minimally-Invasive Foot & Ankle System provides a minimally disruptive, procedurally integrated solution that features specifically designed implants and instrumentation for percutaneous surgery of the foot.  The MICA Minimally-Invasive Foot & Ankle System can be used to treat multiple pathologies including one of the most common, Hallux Valgus, commonly known as bunions.  Compared to a traditional open surgery, the MICA Minimally-Invasive Foot & Ankle System has been shown to provide less pain, shorter operative times and improved cosmesis.

Robert Palmisano, president and chief executive officer, commented, “We have continued to expand our best-in-class foot and ankle product portfolio to meet the needs of orthopaedic physicians and patients and further extend our leadership position in the fast growing lower extremities and biologics markets.  The launch of our unique INVISION Total Ankle Revision System will expand our leadership in total ankle technology and highlights our ability to address the total ankle replacement continuum of care.  In addition, the ORTHOLOC 3Di Ankle Fracture Low Profile System and MICA Minimally-Invasive Foot & Ankle System further enhances our offering in the foot and ankle market space and allows for an improved surgical experience.”

Wright is also conducting medical education and training courses during the AOFAS annual meeting in its mobile training lab.  These courses will address total ankle arthroplasty, Charcot reconstruction and limb salvage, and ankle and hindfoot fusion using Augment®.  More information on Wright Medical’s products can be found at www.wright.com.

Internet Posting of Information

Wright routinely posts information that may be important to investors in the “Investor Relations” section of its website at www.wright.com.  The company encourages investors and potential investors to consult the Wright website regularly for important information about Wright.

About Wright Medical Group N.V.

Wright Medical Group N.V. is a global medical device company focused on extremities and biologics products. The company is committed to delivering innovative, value-added solutions improving the quality of life for patients worldwide.  Wright is a recognized leader of surgical solutions for the upper extremities (shoulder, elbow, wrist and hand), lower extremities (foot and ankle) and biologics markets, three of the fastest growing segments in orthopaedics.  For more information about Wright, visit www.wright.com.

™ and ® denote trademarks and registered trademarks of Wright Medical Group N.V. or its affiliates,  registered as indicated in the United States, and in other countries.  All other trademarks and trade names referred to in this release are the property of their respective owners.

Cautionary Note Regarding Forward-Looking Statements  

This release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “intend,” “could,” “may,” “will,” “believe,” “estimate,” “look forward,” “forecast,” “goal,” “target,” “project,” “continue,” “outlook,” “guidance,” “future,” other words of similar meaning and the use of future dates. Forward-looking statements in this release include, but are not limited to, statements about the performance and market acceptance of the company’s products. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Each forward-looking statement contained in this release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, physician acceptance, endorsement, and use of company products; the effect of regulatory actions, changes in and adoption of reimbursement rates; product liability claims; product recalls; the effects of industry, economic or political conditions outside of the company’s control; competitor activities; and the risks identified under the heading “Risk Factors” in Wright’s Annual Report on Form 10-K for the year ended December 25, 2016 filed by Wright with the SEC on February 23, 2017 and in other subsequent SEC filings by Wright. Investors should not place considerable reliance on the forward-looking statements contained in this release. Investors are encouraged to read Wright’s filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this release speak only as of the date of this release, and Wright undertakes no obligation to update or revise any of these statements. Wright’s business is subject to substantial risks and uncertainties, including those referenced above. Investors, potential investors, and others should give careful consideration to these risks and uncertainties.

Investors & Media:  Julie D. Tracy                                                                                                           Sr. Vice President, Chief Communications Officer Wright Medical Group N.V. (901) 290-5817 julie.tracy@wright.com

Read More
28965.jpg

Active Implants Appoints Charles W. Federico and Gary D. Henley to Board

Posted On July 12, 2017 By OrthoSpineNews In Extremities, Sports Medicine /  

July 12, 2017

MEMPHIS, Tenn.–(BUSINESS WIRE)–Active Implants, a company that develops orthopedic implant solutions, today announced the appointments of orthopedic and sports medicine industry veterans Charles W. Federico and Gary D. Henley to its board of managers.

“Both Charlie and Gary are respected leaders with long-term success in medical and orthopedic device industries, and they bring a wealth of strategic and operational experience to our board,” said Ted Davis, president and chief executive officer of Active Implants. “We believe their diverse leadership experience will strengthen our board, and their insights will be invaluable as we continue to develop the NUsurface Meniscus Implant and fulfill a significant unmet need in the orthopedic market here in the U.S. and worldwide.”

Federico has 44 years of experience in the medical device industry, with significant focus in the sports medicine segment while president and chief executive officer of Orthofix International N.V. and president of Smith & Nephew Endoscopy. Additionally, he has held senior management and sales and marketing positions with Dyonics, General Foods Air Products Corporation, Puritan Bennett Corporation and LSE Corporation. Federico has extensive board experience, including chairman of the board and lead director of MAKO Surgical Corp, sold to Stryker; and a board member at Biomimetic Therapeutics, sold to Wright Medical Group.

Henley has more than 35 years of experience in the orthopedic device industry, including president, chief executive officer and board member of United Orthopedic Group, which was sold to Breg. Previously, he was president and chief executive officer of Wright Medical Group, Inc.; president of Orthofix International N.V.’s Americas Division; president of Smith & Nephew’s Endoscopy Video Division; and president and chief executive officer of Cecorp, Inc. Henley is an experienced board member and industry consultant, most recently serving as executive chairman of the board of directors at OrthAlign, Inc. and a director at Orchid Orthopedic Solutions.

With the appointment of Federico and Henley, Active Implants’ board consists of eight members: Henry Klyce, chairman of the board; Ted Davis, Active Implants CEO; James D. Lackie; William T. Mays, Jr.; Haynes Morris; and Spence Wilson, Jr.

About the NUsurface® Meniscus Implant

The NUsurface® Meniscus Implant is an investigational treatment for patients with persistent knee pain following medial meniscus surgery. It is made from medical grade polymer and, as a result of its unique materials, composite structure and design, does not require fixation to bone or soft tissues. The NUsurface Meniscus Implant mimics the function of the natural meniscus and redistributes loads transmitted across the knee joint. The NUsurface Meniscus Implant has been used in Europe under CE Mark since 2008 and in Israel since 2011. Clinical trials are underway in the U.S., Europe and Israel to verify the safety and effectiveness of the NUsurface Meniscus Implant.

About Active Implants LLC

Active Implants LLC develops orthopedic implant solutions that complement the natural biomechanics of the musculoskeletal system, allowing patients to maintain or return to an active lifestyle. Active Implants is privately held with headquarters in Memphis, Tennessee. European offices are in Haarlem, The Netherlands, with R&D facilities in Netanya, Israel. For more information, visit www.activeimplants.com.

CAUTION Investigational device. Limited by United States law to investigational use.

Contacts

Merryman Communications
Joni Ramirez, 323-532-0746
joni@merrymancommunications.com

Read More

ECA Medical Instruments Sees Major Gains & Market Adoption Of New Sterile-Packed, Disposable Instrument Kits for Orthopaedics

Posted On July 12, 2017 By OrthoSpineNews In Extremities, Top Stories /  

July 12, 2017

Thousand Oaks, CA.—ECA Medical Instruments, the leading designer and manufacturer of single-procedure torque-limiting and fixed-driver surgical instruments and procedural kits for the medical industry and surgeons worldwide, has designed and produced sterile-packed, surgery ready disposable instrument kits for a wide range of trauma and extremity implants used by surgeons for fracture and joint degeneration repair.

Tailored to implant manufacturer specifications these kits are being rapidly adopted across the marketplace to reduce cost, eliminate reprocessing, improve patient safety and provide perfect fixation of implants while reducing risk of surgical site infection.

The fully disposable kits include the full complement of instruments needed by surgeons and OR teams including cannulated fixed drivers, torque limiters, cannulated countersinks and depth gauge instrument, drill guides, guide wires and drill bits. The cannulated instrument design permits minimally invasive surgery (MIS), which reduces OR time, blood loss and patient recovery times. All the instruments are packaged in sterile pack and fully disposable trays.

“We recently launched the industry’s first sterile-packed instrument set for securing cannulated titanium screws and also have deployed sterile pack kits and instruments for hand and wrist repair as well as joint arthroplasty and spine implant product lines,” said James Schultz, ECA’s executive vice president, sales & marketing. 

ECA Medical Instruments Disposable Instrument Kits   

“Single-use instrument kits coupled with sterile packed implants are clearly the way of the future for high volume and relatively low complexity orthopaedic surgeries in both the hospital and outpatient setting,” he said. “We’re excited to partner with major OEMs in the ortho and spine industry and bring these new instrument kits to market.

Single-procedure instruments and procedural kits are providing surgeons and patients alike with a pristine set of ready for surgery instruments for securing a wide range of medical device implants. Sustained benefits include elimination of reprocessing costs, improved OR efficiency, reduced risk of surgical site infection and reduction in hospital and ASC inventory management.

ECA is a one stop shop OEM instrument company providing implant firms with complete product design and development, product and packaging validations, CE Mark and dock to stock operations. This reduces OEM costs and accelerates time to market.

About ECA Medical Instruments

ECA Medical Instruments®, a LongueVue Capital Partners company, was founded in 1979 and located in Thousand Oaks, CA.  ECA is the industry leader in single-procedure torque-limiting instruments and surgical fixation kits. The company has manufactured and delivered over 32 million precision torque instruments to the world’s leading producers of CRM, neuromodulation, cardiovascular and orthopaedic and spine implants resulting in over 500 million precision surgical actuations. Every 20 seconds of every day an ECA torque instrument or procedural kit is used to secure a medical implant—one patient at a time. ECA is an ISO 13485, CE Mark certified and FDA registered company and was named Business of the Year 2012 by the Pacific Coast Business Times. www.ecamedical.com

Read More
DynaForce_Foot-thumb500x500.png

CrossRoads® Extremity Systems, LLC Announces Launch of the DynaFORCE™ Dynamic Compression Fixation System

Posted On July 11, 2017 By OrthoSpineNews In Extremities, Top Stories /  

MEMPHIS, Tenn., July 11, 2017 /PRNewswire/ — CrossRoads® Extremity Systems LLC., a privately held medical device company offering innovative foot & ankle fixation implant systems, announced that it has recently launched the first hybrid fixation system, DynaFORCE™. It represents the pinnacle of plate and nitinol clip fixation, featuring optimized dynamic compression, top loading insertion, and intraoperative placement flexibility with its unique implant and delivery instrument design.

Terrence Philbin, DO, from Columbus, OH, and Stuart Miller, MD, from Baltimore, MD were some of the first surgeons to use the new DynaFORCE system. Per Dr. Miller, “The plate and staple combination is brilliant. The exciting and innovative engineering of the implants and instruments has direct application to foot and ankle fixation.”

“The DynaFORCE system is very intuitive in the O.R.,” Dr. Philbin said. “The ability to use the dynamic compression staple in conjunction with a plate provides strong compression and stability. Another key benefit of nitinol fixation is the continuous compression you get after implantation. I look forward to utilizing DynaFORCE in multiple applications down the road.”

Designed to meet the needs of multiple applications in foot and ankle fixation, the DynaFORCE portfolio consists of a wide variety of plate and clip options that incorporate continuous adaptive compression.

Vernon Hartdegen, Co-Founder of CrossRoads, comments, “DynaFORCE represents our commitment to establishing a positive experience for foot and ankle surgeons and their patients.  The early clinical results are exceptional, and the product adoption is rapidly accelerating.  Early indications are that DynaFORCE will become the leading technology in foot and ankle fixation.”

DynaFORCE is currently wrapping up an alpha launch. Full US market availability is expected in August 2017.

About CrossRoads Extremity Systems

CrossRoads was founded in 2014 and is headquartered in Memphis, TN. CrossRoads has experienced rapid growth through creative product development and a strong distributorship network. CrossRoads’ goal is to provide a steady rhythm of novel and clinically relevant new products that distinguish us from other companies.

In addition to providing novel products, CrossRoads strives to find ways to help hospitals save money and improve efficiency. CrossRoads believes that as customers experience the EcoSMART™ model of using high quality, surgical grade instruments in sterile kits, and then realize the savings from instrument rebates; our EcoSMART Service will become the preferred model of surgeons, O.R. staff, and materials management.

For more information, please visit www.crextremity.com

©2017 CrossRoads Extremity Systems, LLC.  All Rights Reserved

Contact:
Vernon Hartdegen
SVP of Operations for CrossRoads Extremity Systems, LLC
pr@crextremity.com

 

SOURCE CrossRoads Extremity Systems, LLC.

Related Links

http://www.crextremity.com

Read More
variable-angle-LCP-distal-radius-sterile-kit-main-image.png

DePuy Synthes Launches Single Use Kits For Wrist Fracture Surgery

Posted On July 11, 2017 By OrthoSpineNews In Extremities /  

WEST CHESTER, Pa., July 11, 2017 /PRNewswire/ — DePuy Synthes* has introduced the Distal Radius Sterile Kit, a pre-sterilized, single-use kit of instruments and implants to treat wrist fractures. The streamlined kits provide customers with the company’s market-leading plate and screw implants with instrumentation designed to help optimize operating room efficiency and eliminate procedural sterilization costs.

An estimated 640,000 wrist fractures occur annually in men and women of all ages in the United States and are one of the most frequently seen fractures in the emergency room in people under 65.1 With such a high volume of procedures, surgeon and provider customers want a solution that enables high-quality treatment for patients while improving efficiency, reducing costs and minimizing delays associated with instrumentation and sterilization problems. One Canadian study demonstrated that surgical delays as brief as 10 minutes may cost a hospital more than $130,000 in staffing costs alone per year.2

The Distal Radius Sterile Kit consists of one Variable Angle LCP® Two-Column Volar Distal Radius Plate, a distribution of screws, and the required fixation instrumentation—commonly what is needed for up to 80 percent of distal radius fracture cases currently treated with plates and screws. The simplified composition of the kit is designed to drive repeatable, more consistent procedures.

“It’s important in trauma cases for the instrumentation to be arranged in a way that the surgeon can focus on the patient without distraction from the back table,” said Marc Richard**, M.D., Associate Professor, Hand, Upper Extremity and Microvascular Surgery, Department of Orthopaedic Surgery, Duke University Medical Center. “In my experience with these sterile kits, they have helped assure availability of the distal radius plates during unscheduled trauma cases.  Additionally, I have found that the simplified set and instrumentation can help the scrub team preserve operating room efficiency.”

The Distal Radius Sterile kit brings value to healthcare systems by eliminating costs and time for sterilization. A UK industry report cites that single-use kits may save approximately $285 per procedure for sterilization, transport, and handling.3  To learn more about the Distal Radius Sterile Kits, visit www.DePuySynthes.com/DRSK.

“The Distal Radius Sterile Kit is an example of how we are responding to customer needs by providing value beyond the implant,” said I.V. Hall, Global Franchise Leader, DePuy Synthes Trauma. “By combining our market-leading plate and screw solution with single-use instrumentation, we are supporting our customers ranging from academic medical centers to community hospitals in providing high-quality care in an efficient, cost-effective way.”

About DePuy Synthes Companies
DePuy Synthes Companies, part of the Johnson & Johnson Medical Devices Companies***, provides one of the most comprehensive orthopaedics portfolios in the world. DePuy Synthes Companies solutions, in specialties including joint reconstruction, trauma, craniomaxillofacial, spinal surgery and sports medicine, are designed to advance patient care while delivering clinical and economic value to health care systems worldwide. For more information, visit www.depuysynthes.com.

*DePuy Synthes represents the products and services of DePuy Synthes Products, Inc. and its subsidiaries.
**Consultant to DePuy Synthes Trauma
***The Johnson & Johnson Medical Devices Companies comprise the surgery, orthopaedics, and cardiovascular businesses within Johnson & Johnson’s Medical Devices segment.

©DePuy Synthes 2017. All rights reserved
DSUS/TRM/0617/1491

1 Nellans, Kate W., et al. The Epidemiology of Distal Radius Fractures. Hand Clin. 2012 May; 28(2): 113–125.
2 Wong J, Khu KJ, Kaderali Z, Bernstein M. Delays in the operating room: signs of an imperfect system. Canadian Journal of Surgery. 2010;53(3):189-195.
3 Goldrein T, Locsei T, Craigwood, A. DYQ06 – Costs of Orthopaedic Surgery. Innovia Technology Report. 2010. Note: costs were converted from GBP to USD using 2010 conversion rates.

SOURCE DePuy Synthes

 

Read More
Cartiva_SyntheticCartilageImplant_WEB-1.jpg

Cartiva, Inc., Announces Multiple Presentations at American Orthopaedic Foot and Ankle Society Annual Meeting 2017

Posted On July 10, 2017 By OrthoSpineNews In Extremities /  

July 10, 2017

ALPHARETTA, Ga.–(BUSINESS WIRE)–Cartiva, Inc. (Company), a developer of innovative products for treating cartilage damage and osteoarthritis, announced today that clinical data on its Cartiva Synthetic Implant (SCI) will be presented at the American Orthopaedic Foot and Ankle Society (AOFAS) Annual Meeting taking place July 12-15 at the Washington State Convention Center in Seattle, Washington. The AOFAS is a medical specialty society comprised of more than 2,200 orthopaedic surgeons from the US and abroad who specialize in the care of patients with injuries, diseases and other conditions of the foot and ankle. The presentations include:

  • Friday, July 14th 10:15 AM to 10:20 AM, podium presentation by Mark A. Glazebrook, MSc, MD, PhD, FRCSC, “Revision of Implant to Great Toe Fusion: Did We “Burn a Bridge” With a Synthetic Implant Hemiarthroplasty?”
  • Saturday, July 15th 8:20 AM to 8:25 AM, podium presentation by Judith F. Baumhauer, MD, MPH, “Correlation of Hallux Rigidus Coughlin Grade with First MTP Motion, Intra-operative Cartilage Loss and Treatment Success for 1st MTP Arthrodesis and Hemi-Arthroplasty.” This abstract was selected by the AOFAS Program Committee as one of three finalists for the prestigious Roger A. Mann Award. The Mann award is given in recognition of the best clinical paper accepted for presentation at the annual meeting. The winner of the award will be announced during the meeting on Friday, July 14th.
  • Saturday, July 15th 9:10 AM to 9:15 AM, podium presentation by Andrew J. Goldberg, OBE, MD, MBBS, FRCS, FRCS (Tr&Orth), “The Influence of Patient Factors on the Outcome of Synthetic Cartilage Implant Hemiarthroplasty versus First Metatarsophalangeal Joint Arthrodesis in Advanced Hallux Rigidus.”

In addition, the Company will sponsor a symposium on Friday July 14th from 6:30 AM to 8:00 AM, Level 6, Rooms 611 & 612. Entitled “The Difference is DATA™ – Cartiva Synthetic Cartilage Implant for Hallux Rigidus”, the symposium’s faculty includes Judith F. Baumhauer, MD, MPH, Michael J. Coughlin, MD, Timothy R. Daniels, MD, FRCSC, Mark A. Glazebrook, MSc, MD, PhD, FRCSC, David B. Thordarson, MD and Keith L. Wapner, MD.

The Company invites all conference attendees to visit Cartiva exhibitor Booth #1211 for ongoing demonstrations of its Cartiva SCI technology.

About Cartiva, Inc.

Based in Alpharetta, Ga., Cartiva, Inc. develops and markets innovative solutions for patients with cartilage damage and osteoarthritis. Cartiva’s venture investors include New Enterprise Associates and Windham Venture Partners. Additional information is available on the company’s website at www.cartiva.net.

Contacts

Cartiva, Inc.
Peter Pizzo, 770-754-3855
Chief Financial Officer

Read More

Nextremity Solutions, Inc. and Ignite Orthopedics, LLC Form Business Alliance

Posted On July 6, 2017 By OrthoSpineNews In Extremities, Top Stories /  

Warsaw, Indiana, July 05, 2017 — Nextremity Solutions, Inc., a musculoskeletal product development company located in “The Orthopedic Capital of the World” Warsaw, IN, has announced a business alliance with Ignite Orthopedics, LLC. The two medical device companies will be leveraging space, resources and capital.

Ignite Orthopedics, an emerging start-up that shares the same exclusive focus on surgeon specialists, plans to develop and commercialize a unique portfolio of products in areas complimentary to Nextremity Solutions.  Having recently appointed its Board of Directors and completed its first round of funding, Ignite is currently building the infrastructure of the company and will be launching development programs in the near future.

“The Nextremity team is excited about the opportunity to co-labor with Ignite Orthopedics as they start this new venture.  Co-locating, sharing key resources, and providing a bit of capital is a great way for Nextremity to support a talented, like-minded team and help accelerate their strategy.  I’ve worked with co-founders Brian Hodorek and Matt Purdy in the past and have tremendous respect for what they’ve been able to achieve. We are excited to watch what they accomplish and see tremendous long-term value through this alliance, for both our shareholders and for our industry partners,” commented Ryan Schlotterback, Chief Commercial Officer for Nextremity Solutions.

“The alliance with Nextremity creates a very unique opportunity for Matt and I to focus on what we do best with minimal disruption from day to day operational tasks,” said Hodorek.  Purdy added, “In essence, it allows us to dedicate our attention to the needs of our surgeon partners and the patients they serve.”

Nextremity Solutions has historically focused on the Lower Extremity market and is currently working closely with surgeon specialists to develop and commercialize Revenue Ready™ products and solutions focused on musculoskeletal care through its recently launched i3™ Strategic Solutions strategy.

Rod K. Mayer, President and CEO of Nextremity Solutions added, “Nextremity Solutions has always had a very strong product development focus. Since our company was founded, we committed to developing innovative solutions alongside surgeons to develop products that meet unmet needs and improve patient health. Ignite Orthopedics shares this vision and mission. It made perfect sense for our two companies to work together to continue to provide surgeons and patients with products that will meet their musculoskeletal needs.”

Ignite Orthopedics is located within the current Nextremity Solutions offices located at 210 N. Buffalo Street, Warsaw, IN. To learn more about the Ignite Orthopedics’ story, the team or how to engage and connect, visit www.igniteorthopedics.com. 

About Ignite Orthopedics, LLC. 

Ignite Orthopedics, LLC. Is a privately held musculoskeletal product development company committed to partnering with those who share a passion to fuel motion whether it be through new ways to innovate, clinical advancements, or improved patient experiences and outcomes. 

About Nextremity Solutions, Inc.

Nextremity Solutions, Inc. is a privately held medical device company offering innovative solutions and approaches to foot and ankle surgical intervention. The Company’s procedure-ready, sterile implant systems for the correction of foot and ankle pathologies include uniquely precise, proprietary technology designed to achieve repeatable and superior clinical outcomes.

For further information, visit www.nextremitysolutions.com or call Dave Temple, Director of Marketing & Corporate Communications at 574-635-3022.

 

Read More